ALS Fund Talks Investments and Strategy as it Kicks Off $100M Campaign
Summary
With Fund II, Boyce says it will look to invest in companies with a platform or multiple approaches to ALS and/or other diseases in order to create diversity, “So it’s not just one shot and a binary outcome.” “What we are focused on is creating a set of companies that make a diversified portfolio, so that even if we aren’t successful in our initial trials, we’ll generate a return and continue to attract more investor capital to continue investing in our mission,” he tells Xconomy. As part of its collaboration with the venture capital fund, the ALS Association will be investing an undisclosed amount with the goal of raising a total of $100 million. Boyce notes that the venture capital model is very different from the social media sensation that in 2014 raised more than $115 million—but the ability to generate impactful results is the same. The ALS Investment Fund also was an early investor in the West Coast startup Verge Genomics, which is using machine learning to catalyze drug discovery. “That’s something to keep an eye out for.” The fund also holds shares in a Danish biopharmaceutical company, Orphazyme, which is planning a clinical trial for ALS.
Classifications
AskAI Classifications
LabelsLinked Companies
